Filtered By:
Source: Journal of the American College of Cardiology
Condition: Cholesterol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke
ConclusionsIndividuals with hypercholesterolemia and hypertension who fail to take their prescribed statin and antihypertensive medication experience a substantially increased risk of fatal stroke. The risk is lower if the patient is adherent to either one of these therapies.
Source: Journal of the American College of Cardiology - March 29, 2016 Category: Cardiology Source Type: research

Adherence to Medical Therapy and the Global Burden of Cardiovascular Disease ∗
Ischemic heart disease and cerebrovascular disease account for>20% of worldwide mortality and are the 2 leading causes of death on a global basis (1). Although mortality from ischemic heart disease is greater than that from stroke worldwide, the mortality from stroke is actually higher than from ischemic heart disease in 39% of countries. For example, mortality from stroke is generally higher than that for ischemic heart disease in China, Africa, and South America. In addition, stroke disability–adjusted life-year loss rates exceed ischemic heart disease-related disability in 32% of countries (2). Because of this, strate...
Source: Journal of the American College of Cardiology - March 29, 2016 Category: Cardiology Source Type: research

Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
Conclusions: Although statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with progressive CKD, partly offset these gains. Low-cost generic statins appear cost-effective for primary prevention of CVD in patients with mild-to-moderate CKD and hypertension.
Source: Journal of the American College of Cardiology - March 20, 2013 Category: Cardiology Authors: Kevin F. Erickson, Sohan Japa, Douglas K. Owens, Glenn M. Chertow, Alan M. Garber, Jeremy D. Goldhaber-Fiebert Tags: Cardiovascular Risk Source Type: research

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease: A Meta-Analysis
Conclusions: In elderly subjects at high CV risk without established CV disease, statins significantly reduce the incidence of MI and stroke, but do not significantly prolong survival in the short-term.
Source: Journal of the American College of Cardiology - August 16, 2013 Category: Cardiology Authors: Gianluigi Savarese, Antonio M. Gotto, Stefania Paolillo, Carmen D'Amore, Teresa Losco, Francesca Musella, Oriana Scala, Caterina Marciano, Donatella Ruggiero, Fabio Marsico, Giuseppe De Luca, Bruno Trimarco, Pasquale Perrone-Filardi Tags: Cardiometabolic Risk Source Type: research

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results of the Randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) Study
Conclusions: In patients undergoing carotid stenting, a strategy using both a 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin protects against early ischemic cerebral events. These results, obtained along with routine mechanical neuroprotection, provide new evidence of the optimization of drug therapy before percutaneous carotid intervention. (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting [ARMYDA-9 CAROTID]; NCT01572623)
Source: Journal of the American College of Cardiology - March 14, 2013 Category: Cardiology Authors: Giuseppe Patti, Fabrizio Tomai, Rosetta Melfi, Elisabetta Ricottini, Michele Macrì, Pietro Sedati, Arianna Giardina, Cristina Aurigemma, Mario Leporace, Andrea D'Ambrosio, Germano Di Sciascio Tags: Interventional Cardiology Source Type: research

Heart Failure With Preserved Ejection Fraction: Comparison of Patients With and Without Angina Pectoris (From the Duke Databank for Cardiovascular Disease)
This study investigated the characteristics and outcomes of patients with heart failure with preserved ejection fraction (HFpEF) and angina pectoris (AP).Background: AP is a predictor of adverse events in patients with heart failure with reduced EF. The implications of AP in HFpEF are unknown.Methods: We analyzed HFpEF patients (EF ≥50%) who underwent coronary angiography at Duke University Medical Center from 2000 through 2010 with and without AP in the previous 6 weeks. Time to first event was examined using Kaplan-Meier methods for the primary endpoint of death/myocardial infarction (MI)/revascularization/stroke (...
Source: Journal of the American College of Cardiology - October 25, 2013 Category: Cardiology Authors: Robert J. Mentz, Samuel Broderick, Linda K. Shaw, Mona Fiuzat, Christopher M. O'Connor Tags: Heart Failure Source Type: research

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease. Background: The presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque instability and thereby improve clinical outcomes in patients with stable coronary disease. Methods: In a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable coron...
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Stefan M. Nidorf, John W. Eikelboom, Charley A. Budgeon, Peter L. Thompson Tags: Clinical Trial Source Type: research

Remnant Cholesterol: “Non-(HDL-C + LDL-C)” as a Coronary Artery Disease Risk Factor⁎
In this issue the Journal, Varbo et al. () demonstrate that irrespective of the fasting state, the cholesterol transported by remnant lipoproteins is a robust predictor of coronary artery disease (CAD) risk. Their findings provide clarification to the debate regarding triglyceride-rich lipoproteins and atherosclerosis (). Overall, a consensus is emerging on the basis of clinical and population data and genetic studies that fasting and nonfasting plasma triglycerides are predictive of both CAD and stroke risk, although the relationship is attenuated after correction for associated variables, including high-density lipoprote...
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Ruth McPherson Tags: Cardiometabolic Risk: Editorial Comment Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression
Conclusions: The consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Paul M. Lavigne, Richard H. Karas Tags: Cardiometabolic Risk Source Type: research

The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study
This study sought to determine whether ethnic differences in diabetes, dyslipidemia, and ectopic fat deposition account for ethnic differences in incident cardiovascular disease. Background: Coronary heart disease risks are elevated in South Asians and are lower in African Caribbeans compared with Europeans. These ethnic differences map to lipid patterns and ectopic fat deposition. Methods: Cardiovascular risk factors were assessed in 2,049 Europeans, 1,517 South Asians, and 630 African Caribbeans from 1988 through 1991 (mean age: 52.4 ± 6.9 years). Fatal and nonfatal events were captured over a median 20.5-year follo...
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Therese Tillin, Alun D. Hughes, Jamil Mayet, Peter Whincup, Naveed Sattar, Nita G. Forouhi, Paul M. McKeigue, Nish Chaturvedi Tags: Cardiometabolic Risk Source Type: research

Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010
This study sought to characterize the prevalence of metabolic syndrome (MetS), its 5 components, and their pharmacological treatment in U.S. adults by sex and race/ethnicity over time.Background: MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease, and type 2 diabetes mellitus.Methods: Prevalence estimates were estimated in adults (≥20 years of age) from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010 (in 2-year survey waves). The biological thresholds, defined by the 2009 Joint Scientific Statement, were: 1) waist circumference ≥102 c...
Source: Journal of the American College of Cardiology - July 1, 2013 Category: Cardiology Authors: Hiram Beltrán-Sánchez, Michael O. Harhay, Meera M. Harhay, Sean McElligott Tags: Metabolic Syndrome Source Type: research

In Vivo Evaluation of Atherosclerotic Plaque Inflammation and of Anti-Inflammatory Effects of Statins by 18F-Fluorodeoxyglucose Positron Emission Tomography∗
Atherosclerosis is currently no longer considered merely a cholesterol storage disease, but rather a complex process of vascular inflammation . Indeed, various inflammatory cells and, in particular, monocytes and macrophages play a major role in the development, progression, and rupture of atherosclerotic plaques . Atherosclerosis is initiated when blood monocytes and T lymphocytes are attracted by chemokinesis to oxidized apo-B rich lipoproteins in the vessel wall. Expression of vascular cell adhesion molecule-1 and E- and P-selectin by the endothelium allows their adherence and entry into the subendothelial space. Monocy...
Source: Journal of the American College of Cardiology - June 3, 2013 Category: Cardiology Authors: Bernhard L. Gerber Tags: Cardiac Imaging: Editorial Comment Source Type: research

Relationship of Lipoproteins to Cardiovascular Events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.Background: During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.Methods: Subjects taking simvastatin and/o...
Source: Journal of the American College of Cardiology - August 2, 2013 Category: Cardiology Authors: John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O'Brien, William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden Tags: Cardiometabolic Risk Source Type: research

Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication
Conclusions: In patients with clinically manifest vascular disease using no or usual dose lipid-lowering medication, low plasma HDL-C levels are related to increased vascular risk, whereas in patients using intensive lipid-lowering medication, HDL-C levels are not related to vascular risk.
Source: Journal of the American College of Cardiology - August 14, 2013 Category: Cardiology Authors: Anton P. van de Woestijne, Yolanda van der Graaf, An-Ho Liem, Maarten J.M. Cramer, Jan Westerink, Frank L.J. Visseren, SMART Study Group Tags: Cardiometabolic Risk Source Type: research

Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome: Results From the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome)
Conclusions: High-dose rosuvastatin given on admission to statin-naïve patients with ACS who are scheduled for an early invasive procedure can prevent CI-AKI and improve short-term clinical outcome. (Statin Contrast Induced Nephropathy Prevention [PRATO-ACS]; NCT01185938)
Source: Journal of the American College of Cardiology - September 27, 2013 Category: Cardiology Authors: Mario Leoncini, Anna Toso, Mauro Maioli, Francesco Tropeano, Simona Villani, Francesco Bellandi Tags: Cardiac Imaging Source Type: research